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Herpes simplex virus type 1 (HSV-1) infects 60% of the US population, causing painful oral-labial 
infections and in some cases, permanent brain damage and blindness. Currently, all candidate HSV 
vaccines have failed in clinical trials, as they have been unable to stimulate coordinated CD4+ and 
CD8+ T-cell responses. Due to the large size of the genome and the low frequency of HSV-1-
specific T cells, it has been difficult to select the best T cell antigens to be included in a candidate 
vaccine. To overcome this problem, lead author Lichen Jing and Vaccine and Infectious Disease 
Division affiliate investigator David Koelle have developed a novel method to efficiently generate a 
genome-wide map of responsiveness of HSV-1-specific T cells. 
HSV-1-specific CD8+ T cells were detected and enriched using cross-presentation, in which HSV-1 
antigen loaded dendritic cells presented the antigen to the T cells. Next, CD4+ T cells were 
reactivated by exposure to the whole killed HSV-1 antigen. Then, both types of HSV-1-specific T 
cells were enriched by selecting for CD137, a protein that identifies recently activated CD4+ and 
CD8+ T-cells. By sorting these specific cells from study participants, the cells could then be 
expanded for downstream testing to determine which antigens were most reactive. Because each 
person has a unique set of antigen presentation HLA genes, a personalized set of designer cells 
was created for the CD8+ T-cell discovery work. 
The Koelle Lab found that the proteins for HSV-1 genes UL39 and UL46, previously not known to be 
CD8+ T-cell antigens, appeared to be the most useful vaccine candidates for coordinating both CD4 
and CD8 T-cell responses. The gD antigen, which had previously been unsuccessful in a phase III 
clinical trial, was identified as a poor CD8+ T-cell antigen using this novel approach.  Importantly, 
these methods were also successful for radically enriching CD8 and CD4 T-cells reactive with 
vaccinia virus. The methods outlined in this report may help streamline the antigen selection process 
for other pathogens with large genomes. 
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